Theravance Biopharma, Inc. has signed an important agreement and plans to leave the Nasdaq.

Sep 23, 2026, 4:27 PM ETDealRead the original at sec.gov

Neutral

Theravance agreed to be acquired for $17 cash per share plus one contingent value right. The cash equals its market price and the CVR outcome is uncertain, so the deal does not clearly change the company's outlook.

TBPH · Theravance Biopharma, Inc.

AI read · Neutral

The AI's read

The transaction converts public shares into immediate cash and a possible extra payment, which locks in value and ends public reporting. The $17 cash matches the stock's recent price, so shareholders see little clear premium. The contingent value right could add upside, but its timing and amount are uncertain.

Get alerts for TBPH

Follow Theravance Biopharma, Inc. (TBPH) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for TBPH

Free on the App Store and Google Play, or on the web.